Power Alley -- But... Tardy: Amgen's Lobby Spend Up Sharply In Q1 2022, Like Pfizer & Merck Before It...

Yes, I am about a month overdue with this report -- the raw data from the Congressional disclosure forms has been available since April 20. I apologize. [And, since Pfizer is significantly larger on a market cap basis, than either of the others mentioned, we would expect its spend would be larger -- but it is out-sized, still -- compared to its size advantage over the two.]

And you may compare the below to the ones I did on Pfizer here -- and Merck, here, each for the same period as the below. Enjoy -- but that's a. . . lot of. . . scratch, for just one fourth of a one year:

. . .H.R. 3, Prescription drug pricing issues;
H.R. 19 Lower Costs, More Cures Act of 2021;
H.R. 5260 Reduced Costs and Continued Cures Act;
H.R.5376, Build Back Better Act;
S2891 Restoring America Invents Act, patent thickets/product hopping;
HR 4521 Unites States Innovation and Competition Act
of 2021 Issues related to FTC;
Biosimilars reimbursement issues, no specific bill:
Supply Chain Issues, no specific bill;
Issues related to clinical trial diversity, HR 6584 DEPICT Act;
HR5030 DIVERSE Trials Act;
Issues related to biodefense issues, S3799 PREVENT Pandemics Act;
Issues related to cardiovascular disease awareness, no specific bill;
H.R. 5801 HELP Copays Act;
Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters FDA Issues; User Fee Reauthorization (no specific bill);
H.R. 6963, the Accelerated Approval Integrity Act of 2022;
H.R. 7047, a bill to amend Title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes;
H.R. 6000, the Cures 2.0 Act; and
H.R. 7008, the Pre-Approval Information Exchange Act (among other matters). . . .

Now you know -- onward, grinning at the idea of an "over/under" bet -- measured in weeks, before Martin Shkreli sees his halfway house placement revoked, due to a terms of monitored release violation. We shall see. I hope he's learned some. . . self-control, and self-reflection, while away.

नमस्ते